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Background
House Dust Mite (HDM) accounts for 20-25% of the aller-
gic rhinoconjunctivitis disease burden worldwide. Previous
studies have shown immunotherapy using peptides from
Fel d 1 can induce tolerance in cat allergic subjects. This
study identified T-cell epitopes derived from HDM aller-
gens and evaluated their safety and efficacy in a clinical
study.
Methods
Potential T-cell epitopes were identified by algorithm,
screened for ability to stimulate T-cell responses in ex-
vivo blood samples from HDM allergic subjects and tested
to confirm they did not cause basophil histamine release.
A second group of HDM allergic subjects attended a chal-
lenge where Conjunctival Provocation Test (CPT)
response and Early (EPSR) and Late Phase Skin Response
(LPSR) were measured. Subjects were randomised to one
of 5 cohorts of 10 subjects. In each cohort 8 subjects
received HDM peptide antigen desensitisation (PAD)
using the identified T-cell epitope mixture and 2 subjects
received placebo. The first cohort received 4x0.03nmol
4weeks(wk) apart; successive cohorts received 4 adminis-
trations 4wk apart of 0.3, 1, 3 and 12nmol, respectively.
EPSR, LPSR and CPT were re-measured 18-22wk after
starting treatment.
Results
HDM-PAD was safe and well tolerated with no Serious
Adverse Events. The largest number of Treatment Emer-
gent Adverse Events (TEAEs) occurred in the 0.03nmol
group and the least in the 3nmol group. The most
commonly reported TEAEs in subjects who received
HDM-PAD were nasopharyngitis, influenza, gastroenteritis
and nausea. There were no changes in mean FEV1 on dos-
ing days for any dose of HDM-PAD or placebo. Subjects
treated with four of the five HDM-PAD doses showed
changes from baseline in CPT score at 18-22wk of between
-16.7% to -41.4%, compared with no change for placebo.
A statistically significant median %change from baseline in
CPT score of -36.7% (p=0.0257 vsplacebo) and the largest
change in EPSR (median %change -39.19%) and LPSR
(median %change -51.19%) was observed after 3nmol
HDM-PAD.
Conclusions
HDM-PAD is safe and well tolerated when given as 4
intradermal injections 4wk apart, at doses up to 12nmol in
HDM allergic subjects. Reductions in EPSR, LPSR and
CPT after HDM-PAD indicate the identified T-cell epi-
topes have biological activity and merit further evaluation
for treatment of HDM allergy.
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